BioPharma Credit PLC (FRA:B3P)
Germany flag Germany · Delayed Price · Currency is EUR
0.7750
+0.0050 (0.65%)
At close: Nov 28, 2025

BioPharma Credit Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Cash & Equivalents
4.315.62135.05120.5394.71193.27
Upgrade
Cash & Short-Term Investments
4.315.62135.05120.5394.71193.27
Upgrade
Cash Growth
-88.41%-95.84%12.05%27.26%-51.00%-34.85%
Upgrade
Accounts Receivable
54.2131.7120.2319.739.590
Upgrade
Other Receivables
0.460.080.090.110.420.21
Upgrade
Receivables
54.6731.820.3219.8410.010.21
Upgrade
Total Current Assets
58.9837.42155.37140.37104.72193.48
Upgrade
Long-Term Investments
1,0991,1621,2011,2241,2661,195
Upgrade
Total Assets
1,1581,2001,3571,3641,3711,388
Upgrade
Accrued Expenses
7.4916.9415.8724.356.349.39
Upgrade
Other Current Liabilities
-0.95-1.95--
Upgrade
Total Current Liabilities
7.4917.8815.8726.36.349.39
Upgrade
Long-Term Unearned Revenue
-0.06-0.260.56-
Upgrade
Total Liabilities
7.4917.9415.8726.566.99.39
Upgrade
Common Stock
13.7413.7413.7413.7413.7413.74
Upgrade
Additional Paid-In Capital
607.13607.13607.13607.13607.13607.13
Upgrade
Retained Earnings
529.45560.81720716.59742.85758.05
Upgrade
Shareholders' Equity
1,1501,1821,3411,3371,3641,379
Upgrade
Total Liabilities & Equity
1,1581,2001,3571,3641,3711,388
Upgrade
Net Cash (Debt)
4.315.62135.05120.5394.71193.27
Upgrade
Net Cash Growth
-88.41%-95.84%12.05%27.26%-51.00%-34.85%
Upgrade
Net Cash Per Share
0.000.000.100.090.070.14
Upgrade
Filing Date Shares Outstanding
1,1291,1401,2541,3191,3741,374
Upgrade
Total Common Shares Outstanding
1,1291,1861,3031,3191,3741,374
Upgrade
Working Capital
51.4819.53139.5114.0698.38184.08
Upgrade
Book Value Per Share
1.021.001.031.010.991.00
Upgrade
Tangible Book Value
1,1501,1821,3411,3371,3641,379
Upgrade
Tangible Book Value Per Share
1.021.001.031.010.991.00
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.